We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-3.23%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$12.1M
Cap. Flow
+$4.9M
Cap. Flow %
5.13%
Top 10 Hldgs %
84.86%
Holding
21
New
2
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
IMDZ
Immune Design Corp.
IMDZ
+$2.46M
2
SENS icon
Senseonics Holdings Inc
SENS
+$1.81M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$1.16M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$533K

Sector Composition

Rank Sector Weight
1 Healthcare 89.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
1
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$18.1M 18.96%
1,301,413
– –
TARA icon
2
Protara Therapeutics
TARA
$220M
$16.3M 17.03%
50,447
– –
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$14.5M 15.15%
219,901
– –
TBRA
4
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$7.38M 7.72%
589,244
– –
CEMP
5
DELISTED
Cempra, Inc.
CEMP
$6.33M 6.63%
383,935
– –
CHMA
6
DELISTED
Chiasma, Inc. Common Stock
CHMA
$6.01M 6.3%
2,080,595
– –
EVAR
7
DELISTED
Lombard Medical, Inc.
EVAR
$3.79M 3.96%
3,473,452
– –
INNL
8
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$3.07M 3.21%
555,555
– –
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.83M 2.96%
945,757
– –
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$2.8M 2.93%
1,600,000
– –
CLLS
11
Cellectis
CLLS
$277M
$2.66M 2.78%
100,000
– –
DERM
12
DELISTED
Dermira, Inc.
DERM
$2.05M 2.14%
70,000
– –
ADAP
13
DELISTED
Adaptimmune Therapeutics
ADAP
$2.03M 2.13%
250,000
– –
SENS icon
14
Senseonics Holdings Inc
SENS
$263M
$2.03M 2.12%
+25,844
New +$1.81M
IMDZ
15
DELISTED
Immune Design Corp.
IMDZ
$1.61M 1.69%
+197,300
New +$2.46M
AUPH icon
16
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.39M 1.45%
512,036
+423,729
+480% +$1.16M
ANTH
17
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.35M 1.41%
54,749
– –
RGLS
18
DELISTED
Regulus Therapeutics
RGLS
$943K 0.99%
2,728
– –
ACHV icon
19
Achieve Life Sciences
ACHV
$659M
$400K 0.42%
180
– –
EPRS
20
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$4K ﹤0.01%
7,896
– –
CCXI
21
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-215,000
Closed -$533K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2016 Portfolio in Review

As of Q2 2016, Abingworth held 21 positions worth $95.5M, down 11% from $108M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Abingworth deployed $4.9M of net new capital in Q2 2016, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Immune Design Corp.: 197,300 shares worth $1.61M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

On the sell side, the most notable exit was ChemoCentryx, Inc., an estimated $533K sold.

  • Abingworth's largest Q2 2016 buy was Immune Design Corp.: 197,300 shares worth $1.61M.
  • Abingworth added most to Aurinia Pharmaceuticals in Q2 2016, an estimated $1.16M increase.
  • Abingworth fully exited ChemoCentryx, Inc. in Q2 2016, selling an estimated $533K.
  • Abingworth's ten largest holdings make up 85% of its $95.5M portfolio in Q2 2016.
  • Abingworth opened 2 new positions and closed 1 in Q2 2016.
  • Abingworth's portfolio value fell 11% quarter-over-quarter to $95.5M.

Based on Abingworth's 13F filing for Q2 2016, filed 12 Aug 2016.